Aura Biosciences Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer
The company specializes in the use of virus-like particle technology to create targeted therapies that can selectively deliver cancer-fighting agents to tumor cells while minimizing damage to healthy tissues. By leveraging its proprietary platform, Aura aims to advance new treatments for various types of solid tumors, with a strong emphasis on improving patient outcomes and offering safer, more effective options for those battling cancer.
Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety profile.
Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout.
Aura Biosciences, Inc. (NASDAQAURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
Aura Biosciences Inc. (NASDAQAURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
Aura Biosciences Inc. (NASDAQAURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma.
Aura Biosciences, Inc. (NASDAQAURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2023, and provided clinical development and operational highlights.
Aura Biosciences Inc. (NASDAQAURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
Aura Biosciences Inc (NASDAQAURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common st
Gainers PaxMedica, Inc. (NASDAQPXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Gainers Senti Biosciences, Inc. (NASDAQSNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.
